Decoy Therapeutics, Inc. (DCOY)
2.98
-0.08
(-2.61%)
USD |
NASDAQ |
Sep 02, 16:00
2.88
-0.10
(-3.36%)
After-Hours: 20:00
Decoy Therapeutics Net Income (TTM) : -14.45M for June 30, 2026
Net Income (TTM) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Net Income (TTM) Data
| Date | Value |
|---|---|
| June 30, 2026 | -14.45M |
| March 31, 2026 | -13.03M |
| December 31, 2025 | -12.52M |
| September 30, 2025 | -5.005M |
| June 30, 2025 | -5.103M |
| March 31, 2025 | -5.57M |
| December 31, 2024 | -5.576M |
| September 30, 2024 | -4.994M |
| June 30, 2024 | -6.464M |
| March 31, 2024 | -8.917M |
| December 31, 2023 | -12.54M |
| September 30, 2023 | -18.03M |
| June 30, 2023 | -30.00M |
| March 31, 2023 | -30.84M |
| December 31, 2022 | -29.60M |
| September 30, 2022 | -26.97M |
| June 30, 2022 | -15.63M |
| December 31, 2021 | -12.77M |
| September 30, 2021 | -10.43M |
| June 30, 2021 | -8.410M |
| March 31, 2021 | -7.120M |
| December 31, 2020 | -7.352M |
| Date | Value |
|---|---|
| September 30, 2020 | -7.467M |
| June 30, 2020 | -8.380M |
| March 31, 2020 | -7.500M |
| December 31, 2019 | -6.938M |
| September 30, 2019 | -6.148M |
| June 30, 2019 | -3.825M |
| March 31, 2019 | -11.97M |
| December 31, 2018 | -18.67M |
| September 30, 2018 | -25.61M |
| June 30, 2018 | -34.64M |
| March 31, 2018 | -34.39M |
| December 31, 2017 | -34.43M |
| September 30, 2017 | -34.31M |
| June 30, 2017 | -35.61M |
| March 31, 2017 | -38.17M |
| December 31, 2016 | -39.49M |
| September 30, 2016 | -39.49M |
| June 30, 2016 | -37.00M |
| March 31, 2016 | -32.72M |
| December 31, 2015 | -29.14M |
| September 30, 2015 | -24.99M |
| June 30, 2015 | -18.82M |
Net Income Definition
Represents net income for the period and date(s) requested in local currency by default.
Net Income (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Net Income (TTM) Benchmarks
| Palatin Technologies, Inc. | -6.249M |
| Unicycive Therapeutics, Inc. | -35.22M |
| Nuvectis Pharma, Inc. | -30.28M |
| ACADIA Pharmaceuticals, Inc. | 380.48M |
| Alnylam Pharmaceuticals, Inc. | 807.99M |